SMARCA-BD ligand 1 for Protac

CAS No. 1997319-92-2

SMARCA-BD ligand 1 for Protac( —— )

Catalog No. M33230 CAS No. 1997319-92-2

SMARCA-BD ligand 1 for Protac is a compound that binds to SMARCA2, the BAF ATPase subunit, utilizing Protac technology to degrade SMARCA2.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 140 In Stock
10MG 227 In Stock
25MG 385 In Stock
50MG 531 In Stock
100MG 724 In Stock
200MG 986 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SMARCA-BD ligand 1 for Protac
  • Note
    Research use only, not for human use.
  • Brief Description
    SMARCA-BD ligand 1 for Protac is a compound that binds to SMARCA2, the BAF ATPase subunit, utilizing Protac technology to degrade SMARCA2.
  • Description
    SMARCA-BD ligand 1 for Protac is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1997319-92-2
  • Formula Weight
    271.32
  • Molecular Formula
    C14H17N5O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    NC1=C(C=C(N=N1)C2=C(O)C=CC=C2)N3CCNCC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Farnaby W, et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat Chem Biol. 2019 Jul;15(7):672-680.?
molnova catalog
related products
  • Trotabresib

    Trotabresib (CC-90010) is an orally active inhibitor of BET and can be used in studies about advanced solid tumors.

  • WAY-309060

    WAY-309060 is a BRD4 small molecule inhibitor with antitumor activity.

  • SGC-SMARCA-BRDVIII

    SGC-SMARCA-BRDVIII is a potent and selective inhibitor of SMARCA2, SMARCA4, PB1(2), PB1(3) and PB1(5) with Kds of 35 nM, 36 nM, 3.7 μM, 2.0 μM and 13 nM, respectively.